Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucose and cardiovascular risk.

M Fuchs1, J B L Hoekstra, A H Mudde

  • 1Slingeland Hospital, department of Internal Medicine, Doetinchem, The Netherlands.

The Netherlands Journal of Medicine
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor-Associated Ketoacidosis Case Reports.

Acta anaesthesiologica Scandinavica·2026
Same author

Add-on treatment with intermediate-acting insulin versus sliding-scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy: a randomized crossover study.

Diabetes, obesity & metabolism·2016
Same author

The influence of oral contraceptives on overnight 1 mg dexamethasone suppression test.

The Netherlands journal of medicine·2016
Same author

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.

Diabetes, obesity & metabolism·2015
Same author

Physician's attitudes towards diagnosing and treating glucocorticoid induced hyperglycaemia: Sliding scale regimen is still widely used despite guidelines.

Diabetes research and clinical practice·2015
Same author

Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.

Diabetes, obesity & metabolism·2015

New guidelines redefine abnormal glucose tolerance, classifying impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) as intermediate stages. Research indicates plasma glucose levels, even within the normal range, may be linked to cardiovascular risk.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Disorders

Background:

  • The American Diabetes Association and World Health Organization have updated criteria for diabetes mellitus.
  • Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are now recognized as intermediate stages of glucose metabolism.
  • The metabolic syndrome, a cluster of cardiovascular risk factors, often co-occurs with abnormal glucose tolerance.

Purpose of the Study:

  • To review the redefined spectrum of abnormal glucose tolerance.
  • To discuss the role of glucose levels as a cardiovascular risk factor.
  • To examine the relationship between glucose levels and cardiovascular events.

Main Methods:

  • Review of recent research and established guidelines.

Related Experiment Videos

  • Analysis of diagnostic criteria for diabetes, IFG, and IGT.
  • Discussion of the metabolic syndrome and its association with glucose abnormalities.

    • Main Results:

    • Sharpened criteria for diabetes mellitus have been established.
    • IFG and IGT are classified as distinct intermediate stages.
    • Evidence suggests a link between plasma glucose levels, even in the normal range, and cardiovascular risk.

    Conclusions:

    • The redefinition of glucose tolerance provides clearer diagnostic pathways.
    • The association between glucose levels and cardiovascular risk warrants further investigation.
    • Understanding glucose's impact on cardiovascular events is crucial for risk assessment and management.